exelixis

Shares of Exelixis, Inc. (NASDAQ: EXEL) surged higher by more than 7 percent at $5.90 early Tuesday morning after the company announced positive results from its METEOR Phase 3 pivotal trial of cabozantinib. Exelixis' phase 3 pivotal trial involved 658 patients with renal cell carcinoma....

J.P. Morgan is out with its report today on Exelexis (NASDAQ: EXEL), maintaining Neutral. In a note to clients, J.P. Morgan writes, "We are maintaining our Neutral rating on EXEL following a tumultuous ASCO meeting. On the positive side, we are increasingly impressed by the striking bone met...

Piper Jaffray is out with its report on Exelixis (NASDAQ: EXEL), reiterating Overweight. In a note to clients, Piper Jaffray writes, "Bloomberg reported after the close that Exelixis has retained Goldman Sachs to field potential takeover offers around cabozantinib data at ASCO in early June....

In the last six months, Exelixis, Inc. (NASDAQ: EXEL) soared more than 200% on the news that the company is developing a promising drug to combat prostate cancer. Michael Morrissey, CEO of Exelixis, told CNBC that the drug tackles both the tumor and the bone complications (prostate cancer “...

Exelixis (NASDAQ: EXEL) is trading higher today. At last check, EXEL was trading at $7.18, up 5.36% from yesterday.

Piper Jaffray has issued a research report for Exelixis, Inc (NASDAQ: EXEL), stating: "Wholly-owned XL184 is a potent MET, RET and VEGFR2 inhibitor. We see a broad development plan for XL184 with opportunities in multiple tumor types. We look for 1st potential approval in metastatic thyroid cancer...